News
-
February 8, 2021
Read Article
Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis -
February 3, 2021
Read Article
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome -
December 15, 2020
Read Article
Pfizer Doses First Patients as Part of Global Achondroplasia Phase 2 Development Program -
November 4, 2020
Read Article
VectivBio Strengthens Business Development Capabilities with Key Appointments -
June 8, 2020
Read Article
Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal -
May 8, 2019
Read Article
Pfizer Acquires Clinical-Stage Biotech Therachon -
September 4, 2018
Read Article
Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration -
May 3, 2018
Read Article
Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq, Announces Reverse Stock Split -
December 5, 2017
Read Article
Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium -
November 13, 2017
Read Article
Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics -
July 27, 2017
Read Article
PreciThera, Inc. Completes $36M Series A Financing -
April 27, 2017
Read Article
Zymeworks Announces Pricing of Initial Public Offering -
March 29, 2017
Read Article
Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX -
March 21, 2017
Read Article
SutroVax Announces Closing of $64M via Series B Financing -
March 14, 2017
Read Article
CellAegis Devices Announces US$9.5 Million Financing to Support Clinical and Regulatory Advancement of its autoRIC® Device -
November 14, 2016
Read Article
Profound Medical Corp. Completes Previously Announced $17.4M Bought Deal Offering of Common Shares -
November 10, 2016
Read Article
Toronto’s Xagenic Inc. completes successful beta testing of X1 diagnostic system -
November 7, 2016
Read Article
Immunovaccine’s Preclinical DPX-NEO Program Demonstrates Positive Anti-Cancer Activity -
September 28, 2016
Read Article
Venous infers_Early work sufficient to attract $21M for Ilkos leg ulcers effort -
June 8, 2016
Read Article
Immunovaccine Announces Closing of $8M Bought Deal Private Placement Financing -
April 26, 2016
Read Article
Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies -
April 26, 2016
Read Article
Zymeworks Names Diana Hausman, M.D. Chief Medical Officer -
April 20, 2016
Read Article
DalCor raises $100M in series B -
April 19, 2016
Read Article
Biotech upstart gambles $150M believing it can succeed after Big Pharmas failed on CETP -
April 19, 2016
Read Article
With $150M in the bank, Dalcor seeks phase III success with dalcetrapib -
April 19, 2016
Read Article
Startup Aims to Revive Failed Drug -
April 19, 2016
Read Article
Xagenic readies X1 molecular diagnostic beta trials -
March 23, 2016
Read Article
Zymeworks Completes Acquisition of Kairos Therapeutics Creating a Leader in Biologics Drug Discovery and Development -
January 8, 2016
Read Article
Zymeworks Announces $61.5M Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics -
November 9, 2015
Read Article
Investissement Québec invests 10M in CTI Life Sciences Fund II -
August 11, 2015
Read Article
PHEMI Closes $12.2M Venture Financing -
July 23, 2015
Read Article
SutroVax raises $22M in Series A -
June 15, 2015
Read Article
XTuit Pharmaceuticals Closes $22M Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders -
May 6, 2015
Read Article
Impressive Industry Leaders Elected to BIOTECanada Board of Directors -
April 9, 2015
Read Article
NEOMED Announces Appointment of Dr. Laurence Rulleau to its Board of Directors -
January 21, 2015
Read Article
Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene -
January 15, 2015
Read Article
CTI Life Sciences successfully raises new C$ 134 Million venture capital fund -
July 14, 2014
Read Article
Xagenic Announces Second Closing of $25.5M Series B Financing -
July 12, 2013
Read Article
Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M -
October 5, 2012
Read Article
Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec -
February 10, 2012
Read Article
Closing of acquisition of Enobia by Alexion – Yet another successful portfolio exit for CTI Life Sciences Fund -
January 30, 2012
Read Article
Xagenic Inc. Closes C$10M Series A Financing -
December 28, 2011
Read Article
Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP) -
September 27, 2011
Read Article
Medicago Completes $25M Private Placement -
August 29, 2011
Read Article
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies -
August 9, 2011
Read Article
Enobia Pharma Raises US $40 million -
April 5, 2011
Read Article
Medicago Announces Closing of C$17.4 Million Equity Offering -
June 30, 2010
Read Article
Sanofi-Aventis to acquire TargeGen Inc., a US biopharmaceutical company -
June 29, 2010
Read Article
Zymeworks Closes C$3.2M Round of Financing -
February 11, 2010
Read Article
Somnus Therapeutics Closes US$15M Series A Financing with CTI Life Sciences and Care Capital -
December 29, 2009
Read Article
NeurAxon Announces Closing of Convertible Debenture Financing -
August 10, 2009
Read Article
Enobia Pharma Inc. Raises US$50M from Current Investors in Series C Financing -
June 23, 2009
Read Article
Zymeworks Closes C$3.4M Financing Round and Announces Changes to its Board of Directors -
October 15, 2007
Read Article
Chlorion Pharma Inc. Closes C$6.0 million Financing Round -
September 10, 2007
Read Article
Enobia Pharma Inc. Closes C$40.1 million Series B Financing Round -
July 12, 2007
Read Article
TargeGen Inc. Closes $40.0M Series D Financing Round -
October 4, 2006
CTI Life Sciences Fund Will Invest $100 Million in Business Seeds and Start-upsMontreal, October 4, 2006 – The Minister of Economic Development, Innovation and Export Trade, Raymond Bachand, accompanied by the CEO of FIER Partners, L.P., Sylvie Pinsonnault and Ken Pastor, Senior Partner and Associate Director with CTI Capital, has announced an investment of $25 million by FIER Partners in the new CTI Life Sciences Fund.
“With this new commitment, FIER Partners is making its first investment under the new technology company seed investment section that fills a substantial need in the venture capital market in Québec,” Mr. Bachand said. “I am particularly proud that this investment has contributed to setting up CTI Life Sciences Fund, a fund headed by a team of experienced experts that is backed by many other Québec investors,” Minister Bachand added.
CTI Life Sciences Fund has been formed to offer venture capital to first-generation companies in life sciences operating in biotechnology, biopharmaceuticals and medical devices. “The support of FIER Partners and other institutional investors in Québec was crucial in the creation of this fund in Québec, dedicated solely to supporting the creation and development of companies involved in life sciences,” Ken Pastor, Senior Partner of CTI Life Sciences Fund, said.
FIER Partners has invested $25 million in CTI Life Sciences Fund. The remaining capital of $75 million is being provided in particular by the Caisse de dépôt et placement du Québec, the Fonds de Solidarité du Québec, the Régime de rentes du mouvement Desjardins and partners of the fund, Jean-François Leprince, Richard Meadows, Ken Pastor and CTI Capital.
“FIER Partners is very satisfied that it has contributed to the formation of this fund that aims to satisfy a substantial need for financing of companies in life sciences, particularly those at the seeding stage,” explained Sylvie Pinsonnault who added that the substantial capital of $100 million of CTI Life Sciences Fund will enable better development of companies that will receive investments throughout their growth phase.
FIER Partners is one of three components of the Regional Economic Intervention Fund (FIER) set up at the government’s initiative. It consists of a limited partnership whose initial capitalization of $180 million is provided by IQ-FIER, a subsidiary of Investissement Québec, for $90 million, and by three tax-advantaged funds: the Fonds de solidarité FTQ ($50 million), Capital régional et coopératif Desjardins ($25 million) and Fondaction, the CSN development fund for cooperation and employment ($15 million).
FIER Partners L.P. has $80 million available to support the creation of sector development funds that make equity or quasi-equity investments in start-up companies. The limited partnership contributes one dollar for every two dollars sourced from private investors, so that the total capitalization of the sector funds may ultimately reach $240 million. FIER Partners also has $60 million available to support funds that make technology company seed investments. Lastly, it has a $40-million envelope to support developmental projects, mainly in the regions.
Minister Bachand thanked the partners who participated in the creation of CTI Life Sciences Fund. “By making use of effective levers such as FIER Partners and with the contribution of our largest institutional investors, the government intends to support economic sectors that will help Québec to improve its position in relation to global competition. With the addition of the expertise and vitality of our businesspeople, we have the ingredients needed for new companies in the knowledge-based economy to flourish, here and internationally and thus contribute to Québec’s economic prosperity,” Mr. Bachand concluded.